ERBB2 and breast cancer: For patients with HER2 + BC, systemic treatment in general, particularly anti-HER2 targeted therapies such as trastuzumab and lapatinib, was associated with significantly improved patient median survival (Additional file 2: Fig. S5A–C, p = 0.015, 0.0261 and 0.0352, respectively).